• Cyanin Chloride and Barrier Repair in a Psoriasis Model

  2026-10-05

  A 2024 study evaluated cyanin chloride across chemical radical assays, an LPS-stimulated macrophage model, and a cytokine-induced HaCaT psoriasis model. Its main innovation was to connect reduced inflammatory signaling, including STAT3 phosphorylation, with barrier-related outcomes such as transepithelial electrical resistance and filaggrin expression, while remaining limited to preclinical evidence.

• EGFP sgRNA for HeLa: Evidence and Limits

  2026-10-05

  This evidence-led guide explains how an EGFP sgRNA set can be interpreted within multiplexed CRISPR research without confusing catalog specifications with demonstrated editing performance. It connects the R2997 product context to the 2025 review of multiplex genome engineering, emphasizing readout design, evidence strength, and applicability limits.

• Multiplexed CRISPR–Cas: Evidence and Limits

  2026-10-04

  A source-grounded overview of multiplexed CRISPR–Cas research, including its conceptual applications, reported findings, evidence strength, structural-variant risks, and limits of translating review-level evidence to specific targets or products.

• Multiplexed CRISPR: From Reporter to Translation

  2026-10-03

  A source-grounded perspective on how a three-guide EGFP reporter reagent can support translational CRISPR reasoning without overstating what a catalog product can prove. The article connects multiplexed genome engineering, mechanistic validation, evidence boundaries, and strategic study design to the broader framework described by Cheng, Jeong, and Cho in Experimental & Molecular Medicine.

• A40926: Workflow for Cell Wall Antibiotic Research

  2026-10-02

  A40926 is a dalbavancin precursor and mechanistically defined glycopeptide for profiling cell wall inhibition, MRSA susceptibility, and the unusual activity of Neisseria gonorrhoeae. This practical guide connects reference MIC methods with assay design, biosynthetic research, comparative benchmarking, and troubleshooting.

• EPZ-6438: Mapping EZH2-Driven Resistance

  2026-10-01

  EPZ-6438 is a selective EZH2 inhibitor that turns H3K27me3 modulation into a practical tool for dissecting therapy resistance. This article connects its biochemical selectivity with time-resolved melanoma assays, model selection, and interpretation of combination experiments.

• TACE Silencing in Visceral Adipose Macrophages

  2026-10-01

  The 2017 Biomaterials study developed an ATS-9R-based nonviral system for preferential delivery of TACE-silencing cargo to visceral adipose tissue macrophages. By reducing TACE expression in these inflammatory cells, the approach attenuated adipose inflammation and improved obesity-associated type 2 diabetes in mice, providing a mechanistic framework for targeted obesity-associated inflammation research.

• 3D Cardiac Organoid Mapping with Shell MEAs

  2026-09-30

  The reference study introduces shape-adaptive shell microelectrode arrays (MEAs) that conform to cardiac organoids and enable three-dimensional mapping of electrical activation and conduction. By combining electrophysiology, calcium imaging, and pharmacological perturbations including E-4031, the platform provides a practical framework for longitudinal cardiac electrophysiology research and more physiologically informed drug-response analysis.

• ATS-9R for Adipose Gene Silencing Workflows

  2026-09-30

  ATS-9R provides a non-viral route for concentrating shRNA, siRNA, and selected genome-editing cargos in white adipose tissue and adipose tissue macrophages. Its most distinctive use-case is pairing Prohibitin-directed delivery with cell-specific inflammatory readouts for obesity, insulin resistance, and gestational diabetes research.

• Cepharanthine Workflows for Organoid Apoptosis

  2026-09-29

  Cepharanthine supports a staged workflow that moves from stromal-cell viability screening to patient-derived endometrial organoids and lesion-level validation. This article translates its reported apoptosis, DNA-damage, and cell-cycle effects into practical assay choices while separating preclinical endometriosis evidence from oncology applications.

• Dacomitinib Workflows for Pan-HER Cancer Research

  2026-09-29

  Dacomitinib (PF-00299804) supports practical studies of ErbB signaling, apoptosis, cell-cycle arrest, and treatment resistance. This guide also shows how to extend pan-HER experiments into exploratory ferroptosis and mitochondrial-function assays without confusing hypothesis generation with established mechanism.

• ATS-9R/siCcl2 Targets ATMs in GDM

  2026-09-28

  The reference study developed an ATS-9R/siCcl2 complex to suppress Ccl2 expression in adipose tissue macrophages and reduce inflammation-associated insulin resistance in gestational diabetes mellitus. Its main contribution is a cell- and tissue-oriented nonviral delivery strategy supported by human tissue observations, macrophage experiments, and an HFD-induced GDM mouse model.

• How Kinase Inhibitors Promote p38α Dephosphorylation

  2026-09-28

  A preprint reports that three kinase inhibitors both inhibit p38α MAP kinase and accelerate its dephosphorylation by WIP1. Structural comparisons suggest that inhibitor binding exposes an activation-loop phospho-threonine, revealing a way to influence kinase shutdown through conformational control rather than phosphatase recruitment.

• 2'3'-cGAMP (Sodium Salt): STING Research Guide

  2026-09-27

  2'3'-cGAMP (sodium salt) is an endogenous second messenger and direct STING activator used to investigate the cGAS-STING signaling pathway. Its reported high-affinity binding and defined formulation data make it useful for pathway studies, while extracellular degradation and cellular delivery remain important experimental limits.

• Bay 11-7821: Separating NF-κB from HMGB1 Release

  2026-09-26

  Bay 11-7821 (BAY 11-7082) is commonly used to perturb IKK/NF-κB signaling, but inflammatory outputs do not all share the same upstream controls. This article connects its use to lactate-driven HMGB1 release research and explains how to distinguish pathway effects from changes in cell viability or secretion.

7982 records 1/533 page Next 12345 下5页 Last page